New clinical evidence suggests that Novera Retatrutide, a dual-action therapy from Novo Nordisk, could provide a substantial advance in weight loss. Beyond many existing treatments, Retatrutide targets both glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), po